Dr. Stefan Irion is the Senior Vice President of Research at BlueRock Therapeutics, a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. He talks about the company’s Parkinson’s disease trial and the challenges of genetically manipulating stem cells. He also discusses his journey from physician to scientist and his personal connection to Parkinson’s disease.
Dr. Steven Stice is the DW Brooks Distinguished Professor and Director of the Regenerative Bioscience Center at the University of Georgia, and the Co-Founder and Chief Scientific Officer of ArunA Biomedical. He talks about his early work cloning rabbits and reprogramming blastomeres. He also discusses using exosomes to treat neurological diseases, helping trainees move into industry, and preserving endangered species.
Dr. David Hay is the Chair of Tissue Engineering at the University of Edinburgh, where his group is defining novel ways to produce liver tissue from PSCs. They use in vitro derived tissue to better model human liver physiology and to develop supportive cell based therapies for disease. Dr. Hay also founded Stimuliver, a company that is developing a disruptive liver implant to treat critically failing liver function in humans. He talks about hepatocyte differentiation, liver disease modeling, and automating the production of cell therapies.
Dr. Marinna Madrid is Co-Founder of Cellino, an early-stage biotechnology company seeking to make personalized, autologous cell therapies viable at large scale for the first time. Cellino’s platform combines label-free imaging and high-speed laser editing with machine learning to automate cell reprogramming, expansion, and differentiation in a closed cassette format, enabling thousands of patient samples to be processed in parallel in a single facility.
Dr. Nicole Quinn is the Associate Director of Scientific Communications at STEMCELL Technologies, and one of the people hard at work behind the scenes of the Stem Cell Podcast. After completing her PhD in genomics and discovering her love of communicating science, Nicole left the bench to pursue a science communications career in the biotech industry.